Takeda is dedicated to pharmaceutical innovation and tackling amongst others diseases for which there is currently no cure. We are expanding continuously into new ﬁelds of treatment and therapy, worldwide and in our region, where we focus on inﬂammatory bowel diseases, oncology, immunology and rare diseases.
Gastrointestinal (GI) diseases can be complex, debilitating and life-changing. Takeda is driven to improving the lives of patients with GI diseases through the delivery of innovative medicines, dedicated patient disease management support and the evolution of the healthcare environment.
Takeda is leading in gastroenterology in areas associated with high unmet needs, such as inﬂammatory bowel disease (IBD), short bowel syndrome (SBS) and acid-related diseases (for more info takeda.com/what-we-do/research-and-development/our-pipeline/).
C-ANPROM/BE/ENTY/0060 - Feb 2022